Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Lenvatinib is a multi-targeted tyrosine kinase inhibitor.
• It targets key receptors involved in tumor angiogenesis, including VEGFR, FGFR, PDGFRα, KIT, and RET.
• Tumor angiogenesis is critical for the growth and metastasis of various solid tumors.

Purpose of the Study:

• To review the current status of lenvatinib.
• To discuss the toxicity profile of lenvatinib.
• To explore the future prospects of lenvatinib in treating specific cancers.

Main Methods:

• Review of Phase I clinical trials conducted globally.
• Analysis of lenvatinib's mechanism of action.
• Compilation of data on observed therapeutic effects and adverse events.

Main Results:

• Lenvatinib demonstrated tumor shrinkage in thyroid cancer, endometrial cancer, melanoma, renal cell carcinoma, sarcoma, and colon cancer.
• Key adverse events include hypertension, proteinuria, diarrhea, and delayed wound healing.
• The drug shows promise for treating thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and lung cancer.

Conclusions:

• Lenvatinib is a promising therapeutic agent for multiple solid tumors.
• Effective management of adverse events is essential for lenvatinib therapy.
• Further research into lenvatinib's application in various cancers is warranted.